Arctic Bioscience - Primary insiders who have provided bank guarantee

01 Apr 2026 10:56 CEST

Reference is made to the stock exchange release from earlier today, 1 April 2026
regarding new long-term financing, including agreements with shareholders who
have provided guarantees for the new financing.

The following companies closely related to primary insiders are a part of the
shareholders which have provided guarantees for the new financing:

· Ronja Capital AS, a company closely related to Board Member Tore Tønseth,
NOK 10,0 million
· Vartdal Holding AS, a company closely related to Board Member Jan Endre
Vartdal, NOK 1,5 million
· Brødrene Vartdal AS, a company closely related to Board Member Jan Endre
Vartdal, NOK 1,5 million

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
§ 5-12.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site